stockrowLineage Cell Therapeutics, Inc.
LCTXLineage Cell Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 53.2% from fiscal 2024.
- Revenue
- −61.3%
- EPS
- +104.8%
- Free cash flow
- −32.4%
- Total debt
- −68.8%
Quarter to June 2026, against a year earlier
Follow LCTX
Alert me
Lineage Cell Therapeutics, Inc. (LCTX) EV/Sales
As of 6 November 2026, Lineage Cell Therapeutics, Inc. (LCTX) trades at a EV/Sales of 15.6×. Over the past ten years it has ranged from 4.2× (April 2025) to 243× (June 2021); the current reading is higher than 16% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 22.6× | 309.49% |
| FY2024 | 5.5× | (67.73%) |
| FY2023 | 17.1× | 66.27% |
| FY2022 | 10.3× | (87.06%) |
| FY2021 | 79.4× | (34.85%) |
| FY2020 | 122× | 333.21% |
| FY2019 | 28.1× | 65.39% |
| FY2018 | 17.0× | (73.76%) |
| FY2017 | 64.8× | 15.29% |
| FY2016 | 56.2× | 78.63% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 21.1× | (6.58%) |
| Mar 2026 | 22.6× | 0.06% |
| Dec 2025 | 22.6× | (29.51%) |
| Sep 2025 | 32.0× | 111.07% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −13.5× |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| SPRY ARS Pharmaceuticals, Inc. compare | 2.6× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.1× |
| LCTX Lineage Cell Therapeutics, Inc. | 15.6× |
| CAMP CAMP4 Therapeutics Corporation compare | 36.7× |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)